At Boston Heart, we view compliance and quality as one of the most essential parts of our business. We are committed to quality and have implemented policies, processes, and procedures to ensure that quality standards are achieved and exceeded.

Boston Heart Licenses and Accreditations

Laboratory Accreditations and Licenses

All laboratory tests are performed in our CAP-accredited, CLIA-certified clinical laboratory in Framingham, Massachusetts.


College of American Pathologists
Certificate of Accreditation
200 Crossing Boulevard
CAP #9283394
Expires 03/03/2026

Clinical Laboratory Improvement Amendments (CLIA)
Certificate of Accreditation
200 Crossing Boulevard
CLIA #22D2100622
Expires 10/20/2025

State Licenses By Building

200 Crossing Boulevard

State of California
Clinical Laboratory License
Laboratory ID #CDS 00800630
Expires 02/25/2025

Medical Laboratory Permit
License # 2405
No Expiration

The Commonwealth of Massachusetts
Clinical Laboratory License
License # 5401
Expires 11/15/2025

New Jersey Department of Health
Clinical Laboratory License
CLIS ID #0012397
Expires 12/31/2024

New York State Department of Health
Clinical Laboratory License
PFI 9021
Expires 06/30/2024

Clinical Laboratory Permit
Laboratory ID #034779
Expires 08/15/2024

State of Rhode Island and Providence Plantations
Out of State Clinical Laboratory License
License # LCO00959
Expires 12/30/2024

Boston Heart Diagnostics Laboratory Directors

Marianna Fernandes
Director of Operations

Ernst J. Schaefer, M.D.
Laboratory Director and Chief Medical Officer

Boston Heart Diagnostics Compliance Officer

Serena Beck CHC
Chief Compliance and Privacy Officer

Boston Heart Diagnostics Security Officer

Tim Ghetti
Director, Infrastructure & Technology Support


Boston Heart is focused on helping healthcare providers and patients characterize disease, individualize treatments, and engage patients in their own heart health, in compliance with applicable laws and regulations. As Boston Heart fully cooperates with ongoing investigations, our policy is to not comment on pending litigation.